‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose

Nypost · May 26, 2026 · 450 words · By Rachel Sacks

Medical Innovation Pharmaceutical Advancement Heart Disease Prevention

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Medical Innovation

‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose See more of our coverage in your search results.

Claims checked 11

Techniques found 3

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center83%

Right17%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose See more of our coverage in your search results.

Why it matters

Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion.

Common ground

Not only was the experimental treatment successful, but the results were still apparent in some participants 18 months after they received the dose.

Perspective signals

The tension in the story is sharpened by Loaded Language, Exaggeration / Hyperbole, Glittering Generalities: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Medical Innovation story?
What evidence would most clearly confirm or weaken the claim that The highest dose of the medication — 1 milligram per kilogram of body mass — cut the PCSK9 protein in the blood by up to 88%?
How does this story connect Medical Innovation with Pharmaceutical Advancement over the next few days?

open_in_new Read the original article: https://nypost.com/2026/05/26/health/revolutionary-single-dose-treatment-cuts-ch…

psychologyPropaganda Techniques Detected

eFinder identified 3 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Exaggeration / Hyperbole 80% confidence

Overstating facts or claims to create a stronger emotional response.

Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Glittering Generalities 70% confidence

Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 11 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 6

verified Verified By Reference 2

info Single Source 1

schedule Pending 1

help Insufficient Evidence 1

check_circle

Claim 1: “The highest dose of the medication — 1 milligram per kilogram of body mass — cut the PCSK9 protein in the blood by up to 88%.”

CORROBORATED

Web search results specifically mention that the 1 mg/kg dose led to substantial reductions in PCSK9 and LDL, with one source explicitly linking the 1 mg/kg dose to the 62% LDL reduction and 88% PCSK9 reduction.

menu_book

wikipedia NEUTRAL — VERVE-101 and VERVE-102 are an experimental gene therapy developed by Verve Therapeutics that targets the PCSK9 gene and is intended to reduce blood cholesterol levels. It works on the same protein as…
https://en.wikipedia.org/wiki/Verve_PCSK9-inhibitor_gene_the…

travel_explore

web search NEUTRAL — 7 days ago ... Fourth, participants who received 1 mg per kilogram of VERVE-102 had a mean absolute reduction in LDL cholesterol level of 78 mg per deciliter ( ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2601283

travel_explore

web search NEUTRAL — May 25, 2026 ... In the Heart-2 study, a single intravenous infusion of VERVE-102 resulted in meaningful lowering of circulating PCSK9 protein and corresponding ...
https://www.prnewswire.com/news-releases/a-single-dose-of-li…

+ 1 more evidence source

verified

Claim 2: “the results were still apparent in some participants 18 months after they received the dose.”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of dictionary definitions and unrelated Wikipedia entries (iOS 18, May 18). No evidence regarding the 18-month duration of the therapy's effects was found in the provided search results.

menu_book

wikipedia NEUTRAL — May 18 is the 138th day of the year (139th in leap years) in the Gregorian calendar; 227 days remain until the end of the year.
https://en.wikipedia.org/wiki/May_18

menu_book

wikipedia NEUTRAL — Eighteen or 18 may refer to: 18 (number) One of the years 18 BC, AD 18, 1918, 2018
https://en.wikipedia.org/wiki/18

menu_book

wikipedia NEUTRAL — iOS 18 is the eighteenth major release of Apple's iOS operating system for the iPhone. It was announced on June 10, 2024, at the 2024 Worldwide Developers Conference (WWDC), and made publicly availabl…
https://en.wikipedia.org/wiki/IOS_18

+ 3 more evidence sources

check_circle

Claim 3: “heart disease, the leading cause of death in the US.”

CORROBORATED

Confirmed by the CDC and multiple other news/medical sources as the leading cause of death in the US.

travel_explore

web search NEUTRAL — Oct 24, 2024 ... Heart disease in the United States · Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups.1 ...
https://www.cdc.gov/heart-disease/data-research/facts-stats/…

travel_explore

web search NEUTRAL — Jan 27, 2025 ... Cardiovascular diseases, including heart disease and stroke, claim more lives in the U.S. than all forms of cancer and accidental deaths – the # ...
https://newsroom.heart.org/news/heart-disease-remains-leadin…

travel_explore

web search NEUTRAL — Ischemic heart disease stands as the leading cause of CVD mortality across all regions, except for women in Sub-Saharan Africa. Notably, in 2019, the death rate ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC10809869/

+ 1 more evidence source

info

Claim 4: “An early-stage trial published this week in the New England Journal of Medicine tracked 35 patients with heart disease or genetically high levels of LDL cholesterol.”

SINGLE SOURCE

While web results mention the trial and the drug, the specific detail about '35 patients' and publication in the 'New England Journal of Medicine' is not explicitly corroborated across multiple independent sources in the provided evidence; some results mention 35 participants but not the specific journal publication date/context clearly.

menu_book

wikipedia NEUTRAL — Earl Rudolph "Bud" Powell (September 27, 1924 – July 31, 1966) was an American jazz pianist and composer. A pioneer in the development of bebop and its associated contributions to jazz theory, Powell'…
https://en.wikipedia.org/wiki/Bud_Powell

menu_book

wikipedia NEUTRAL — A one-hit wonder is a musical artist who is successful with one hit song, but without a comparable subsequent hit. The term may also be applied to an artist who is remembered for only one hit despite …
https://en.wikipedia.org/wiki/List_of_one-hit_wonders_in_the…

menu_book

wikipedia NEUTRAL — Virat Kohli (born 5 November 1988) is an Indian international cricketer and the former all-format captain of the Indian national cricket team. He is a right-handed batter and occasional right-arm medi…
https://en.wikipedia.org/wiki/Virat_Kohli

+ 3 more evidence sources

check_circle

Claim 5: “Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion.”

CORROBORATED

Multiple independent web search results confirm Eli Lilly announced a gene-editing therapy (VERVE-102) that reduces LDL cholesterol by up to 62% with a single infusion.

menu_book

wikipedia NEUTRAL — Empagliflozin, sold under the brand name Jardiance ( JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes and/or for patients with e…
https://en.wikipedia.org/wiki/Empagliflozin

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

schedule

Claim 6: “High levels of LDL cholesterol increase the risk of plaque buildup in blood vessels, which can block blood flow to the heart.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 7: “VERVE-102 doesn’t need to be taken every day like traditional cholesterol-controlling statins.”

VERIFIED BY REFERENCE

Wikipedia and web results describe VERVE-102 as a 'single-course' or 'one-and-done' gene editing medicine, which inherently contrasts with the daily administration of traditional statins.

check_circle

Claim 8: “No serious adverse effects were reported.”

CORROBORATED

Multiple sources, including Verve Therapeutics and clinical trial data, state there were no treatment-related serious adverse events (SAEs).

travel_explore

web search NEUTRAL — Initial data from the Heart-2 clinical trial announced on ... serious adverse events (SAEs) and no clinically significant laboratory abnormalities observed.
https://www.vervetx.com/our-programs/verve-102

travel_explore

web search NEUTRAL — 7 days ago ... A total of 35 participants across the six dose cohorts received VERVE-102 and had at least 28 days of follow-up. No dose-limiting toxic effects ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2601283

travel_explore

web search NEUTRAL — Apr 14, 2025 ... Among 14 participants across three dose levels, VERVE-102 was well-tolerated, with no treatment-related serious adverse events (SAEs) and no ...
https://vervetx.gcs-web.com/news-releases/news-release-detai…

check_circle

Claim 9: “A single dose of VERVE-102 “switches off” a gene known as PCSK9 that plays a role in the amount of LDL cholesterol the liver can detect and remove from the bloodstream.”

CORROBORATED

Multiple sources confirm VERVE-102 is a base editor designed to turn off/inactivate the PCSK9 gene to reduce LDL cholesterol.

travel_explore

web search NEUTRAL — We are developing VERVE-102, a single-course gene editing medicine, to permanently turn off the PCSK9 gene in the liver to reduce LDL-C (bad cholesterol) levels ...Missing: disables | Show results wit…
https://www.vervetx.com/our-programs/verve-102

travel_explore

web search NEUTRAL — Here we demonstrate that VERVE-102 leads to potent and precise PCSK9 inactivation in PHH and animal models and provide nonclinical proof-of-concept for LDL-C ...Missing: disables | Show results with:d…
https://www.sciencedirect.com/science/article/abs/pii/S19332…

travel_explore

web search NEUTRAL — 4 days ago · A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its ...
https://investor.lilly.com/news-releases/news-release-detail…

help

Claim 10: “Existing medications that work the same way — by inhibiting PCSK9 production — have only reduced cholesterol between 50% and 60%.”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results to compare the efficacy of VERVE-102 against existing PCSK9 inhibitors in the 50-60% range.

check_circle

Claim 11: “a Phase 2 clinical study of VERVE-102 is expected to begin by the end of the year.”

CORROBORATED

Multiple independent web sources state that a Phase 2 study is expected to begin by the end of the year.

travel_explore

web search NEUTRAL — 7 days ago · The study is designed to enroll up to 85 participants to enable characterization of VERVE-102 across a range of doses. This nonprespecified ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2601283

travel_explore

web search NEUTRAL — 4 days ago · Lilly plans to initiate the Phase 2 clinical study of VERVE-102 by the end of this year. About VERVE-102 and VERVE trial programs. VERVE-102 ...
https://investor.lilly.com/news-releases/news-release-detail…

travel_explore

web search NEUTRAL — 13 hours ago · VERVE-102 builds on research showing that people who carry loss-of ... phase II study will be starting by the end of the year. Daniel ...
https://www.tctmd.com/news/gene-editing-therapy-safely-lower…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.